ESG

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

Estonia's top utility secures key financing for a massive infrastructure upgrade. We decode the risks, rewards, and long-term impact for investors.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

A new solar-plus-storage project in Sicily showcases how tailored energy solutions can boost industrial autonomy, cut costs, and withstand harsh climates.

A new 8MWh energy storage system in Matsusaka showcases how advanced technology is helping Japan balance industrial power with its green energy ambitions.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

Glance is partnering with IAS to bring ad verification to 250M+ users in India and Indonesia, a strategic move to combat fraud and lure premium brands.

Tariff relief was a temporary fix. A powerful federal tax credit offers farmers a sustained way to fund the innovation they perform every day.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

T1 Energy is raising massive capital for its G2_Austin plant and to comply with federal rules, betting big on an American-made clean energy supply chain.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

How a bold $100M pandemic-era investment in a NYC landmark defied market gloom, achieving 100% occupancy and setting a new standard for office resilience.

WelcomeVille Investment Association is launching a platform to fix 'cognitive drift'. Is this the future of professional development or a niche experiment?